Characteristics of BPH Patients with Finasteride therapy in Essential Hypertension Patients – a systematic review

Abstract

Background
Benign prostatic hyperplasia (BPH) is not life threatening, but it is linked to developing cardiovascular diseases, sleep disturbances, mental health issues, sexual dysfunction, and others. Individuals with BPH also experience comorbidities that are associated with the ageing process such as cardiovascular disease (67.7%), hyperlipidemia (57.2%), and hypertension (54.4%). Therapeutic interventions can be employed based on the seriousness of symptoms while patients suffering from moderate to severe symptoms might use medicinal care as a treatment such as 5-alpha reductase inhibitors (finasteride). The use of finasteride is commonly associated with decrease in sexual desire, erectile dysfunction, reduced volume of ejaculate, gynecomastia, and orthostatic hypotension. No research has been conducted on the impact of using finasteride to patients with benign prostatic hyperplasia (BPH) who also have essential hypertension. The use of finasteride as a treatment for BPH might affect individuals with essential hypertension.
Objective
To examine the specific characteristics of patients with benign prostatic hyperplasia (BPH) who undergo finasteride therapy in individuals with essential hypertension.
Methods
This research employs a systematic review and Meta-analysis (PRISMA). The systematic review procedure involves thorough preparation and sequencing, distinguishing it significantly from methods that merely provide literature studies. A targeted search is conducted using databases like Google Scholar, Science Direct, PMC, and Springer Link, using keywords such as "benign prostate hyperplasia", "hypertension", and "finasteride". A total of 8,042 journal articles meet the evaluation criteria.